BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

915 related articles for article (PubMed ID: 22136265)

  • 1. Papillary thyroid carcinoma patients assessed to be at low or intermediary risk after primary treatment are at greater risk of long term recurrence if they are thyroglobulin antibody positive or do not have distinctly low thyroglobulin at initial assessment.
    Soyluk O; Boztepe H; Aral F; Alagol F; Özbey NC
    Thyroid; 2011 Dec; 21(12):1301-8. PubMed ID: 22136265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term outcome of comprehensive central compartment dissection in patients with recurrent/persistent papillary thyroid carcinoma.
    Clayman GL; Agarwal G; Edeiken BS; Waguespack SG; Roberts DB; Sherman SI
    Thyroid; 2011 Dec; 21(12):1309-16. PubMed ID: 22136266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact factors for the outcome of the first
    Shangguan L; Fang S; Zhang P; Han S; Shen X; Geng Y; Luo D; Zhao C
    Ann Nucl Med; 2019 Mar; 33(3):177-183. PubMed ID: 30515649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The value of diagnostic whole-body scanning and serum thyroglobulin in the presence of elevated serum thyrotropin during follow-up of anti-thyroglobulin antibody-positive patients with differentiated thyroid carcinoma who appeared to be free of disease after total thyroidectomy and radioactive iodine ablation.
    Rosario PW; Mineiro Filho AF; Lacerda RX; dos Santos DA; Calsolari MR
    Thyroid; 2012 Feb; 22(2):113-6. PubMed ID: 22224815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extranodal extension of metastatic papillary thyroid carcinoma: correlation with biochemical endpoints, nodal persistence, and systemic disease progression.
    Lango M; Flieder D; Arrangoiz R; Veloski C; Yu JQ; Li T; Burtness B; Mehra R; Galloway T; Ridge JA
    Thyroid; 2013 Sep; 23(9):1099-105. PubMed ID: 23421588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pre-ablation stimulated thyroglobulin is a better predictor of recurrence in pathological N1a papillary thyroid carcinoma than the lymph node ratio.
    Chang YW; Kim HS; Jung SP; Kim HY; Lee JB; Bae JW; Son GS
    Int J Clin Oncol; 2016 Oct; 21(5):862-868. PubMed ID: 26837274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Impact of Detectable Antithyroglobulin Antibodies Below the Reference Limit (Borderline) in Patients with Papillary Thyroid Carcinoma with Undetectable Serum Thyroglobulin and Normal Neck Ultrasonography After Ablation: A Prospective Study.
    Côrtes MCS; Rosario PW; Oliveira LFF; Calsolari MR
    Thyroid; 2018 Feb; 28(2):229-235. PubMed ID: 29325506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive Value of Serum Thyroglobulin for Structural Recurrence Following Lobectomy for Papillary Thyroid Carcinoma.
    Xu S; Huang H; Zhang X; Huang Y; Guan B; Qian J; Wang X; Liu S; Xu Z; Liu J
    Thyroid; 2021 Sep; 31(9):1391-1399. PubMed ID: 34340593
    [No Abstract]   [Full Text] [Related]  

  • 9. Patients with Papillary Thyroid Carcinoma at Intermediate Risk of Recurrence According to American Thyroid Association Criteria Can Be Reclassified as Low Risk When the Postoperative Thyroglobulin Is Low.
    Rosario PW; Furtado Mde S; Mourão GF; Calsolari MR
    Thyroid; 2015 Nov; 25(11):1243-8. PubMed ID: 26359309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Undetectable thyroglobulin after total thyroidectomy in patients with low- and intermediate-risk papillary thyroid cancer--is there a need for radioactive iodine therapy?
    Ibrahimpasic T; Nixon IJ; Palmer FL; Whitcher MM; Tuttle RM; Shaha A; Patel SG; Shah JP; Ganly I
    Surgery; 2012 Dec; 152(6):1096-105. PubMed ID: 23158181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The utility of lymph node mapping sonogram and thyroglobulin surveillance in post thyroidectomy papillary thyroid cancer patients.
    Miah CF; Zaman JA; Simon M; Davidov T; Trooskin SZ
    Surgery; 2014 Dec; 156(6):1491-6; discussion 1496-7. PubMed ID: 25456939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serial post-surgical stimulated and unstimulated highly sensitive thyroglobulin measurements in low- and intermediate-risk papillary thyroid carcinoma patients not receiving radioactive iodine.
    Kashat L; Orlov S; Orlov D; Assi J; Salari F; Walfish PG
    Endocrine; 2016 Nov; 54(2):460-466. PubMed ID: 27189148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Postoperative stimulated thyroglobulin of less than 1 ng/ml as a criterion to spare low-risk patients with papillary thyroid cancer from radioactive iodine ablation.
    Rosario PW; Mineiro Filho AF; Prates BS; Silva LC; Calsolari MR
    Thyroid; 2012 Nov; 22(11):1140-3. PubMed ID: 23050786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Papillary thyroid carcinomas with biochemical incomplete or indeterminate responses to initial treatment: repeat stimulated thyroglobulin assay to identify disease-free patients.
    Lamartina L; Montesano T; Trulli F; Attard M; Torlontano M; Bruno R; Meringolo D; Monzani F; Tumino S; Ronga G; Maranghi M; Biffoni M; Filetti S; Durante C
    Endocrine; 2016 Nov; 54(2):467-475. PubMed ID: 26668060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can the follow-up of patients with papillary thyroid carcinoma of low and intermediate risk and excellent response to initial therapy be simplified using second-generation thyroglobulin assays?
    Rosario PW; Mourão GF; Calsolari MR
    Clin Endocrinol (Oxf); 2016 Oct; 85(4):596-601. PubMed ID: 26940991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin?
    Vera P; Kuhn-Lansoy C; Edet-Sanson A; Hapdey S; Modzelewski R; Hitzel A; d'Anjou J; Basuyau JP
    Thyroid; 2010 Jan; 20(1):15-23. PubMed ID: 20017617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Individualized Follow-Up Strategy for Patients with an Indeterminate Response to Initial Therapy for Papillary Thyroid Carcinoma.
    Oh HS; Ahn JH; Song E; Han JM; Kim WG; Kim TY; Kim WB; Shong YK; Jeon MJ
    Thyroid; 2019 Feb; 29(2):209-215. PubMed ID: 30384812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In search of an unstimulated thyroglobulin baseline value in low-risk papillary thyroid carcinoma patients not receiving radioactive iodine ablation.
    Angell TE; Spencer CA; Rubino BD; Nicoloff JT; LoPresti JS
    Thyroid; 2014 Jul; 24(7):1127-33. PubMed ID: 24697314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reoperative lymph node dissection for recurrent papillary thyroid cancer and effect on serum thyroglobulin.
    Hughes DT; Laird AM; Miller BS; Gauger PG; Doherty GM
    Ann Surg Oncol; 2012 Sep; 19(9):2951-7. PubMed ID: 22526913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum thyroglobulin levels at the time of 131I remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with differentiated thyroid carcinoma.
    Kim TY; Kim WB; Kim ES; Ryu JS; Yeo JS; Kim SC; Hong SJ; Shong YK
    J Clin Endocrinol Metab; 2005 Mar; 90(3):1440-5. PubMed ID: 15613412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.